India indapamide market was valued at $11.2 million in 2025 and is projected to reach $15.0 million by 2035, growing at a CAGR of 3.0% from 2026 to 2035. The India indapamide market is supported primarily by the continuing need for pharmacological management of hypertension and the use of diuretic-based therapies within cardiovascular treatment. Indapamide is available in India as both a standalone antihypertensive and as part of fixed-dose combinations with other blood-pressure-lowering agents. Sustained-release formulations remain an important product format because they provide an established option for longer-duration blood-pressure management. The market also includes a broad generic and branded-generic supplier base, increasing product availability across prescription channels. Recent Indian clinical evidence has further examined indapamide in combination regimens for hypertension management.
Sustained-Release Formulations
Sustained-release indapamide remains an important trend within the Indian market because commercially available products include established prolonged-release formulations. Servier India markets Natrilix SR 1.5 mg, while several Indian manufacturers and marketers offer alternative sustained-release products. The formulation is particularly relevant to chronic hypertension treatment because it is designed for prolonged drug release rather than immediate release. Recent Indian product listings also show continued availability of indapamide sustained-release tablets from multiple suppliers. This indicates continued manufacturer participation in the sustained-release segment alongside established branded products.
Combination Antihypertensive Therapy
Combination therapy is an important market trend because indapamide is increasingly represented in fixed-dose products alongside other antihypertensive agents. Products marketed in India include combinations with amlodipine, perindopril and telmisartan, allowing indapamide to be incorporated into multi-drug treatment approaches. Zydus, Servier, Lupin, Glenmark and Eris are among companies with documented indapamide-containing combination products. Indian clinical research published in 2025 also evaluated amlodipine–indapamide and perindopril–indapamide combinations in patients with hypertension.
Market Segmentation
Sustained-Release Tablets Segment to Lead the Market with the Largest Share
Sustained-release tablets represent an important subsegment of the India indapamide market because several established products use this formulation. Natrilix SR, Diurix SR, Indap SR, and other products demonstrate continued availability of sustained-release indapamide through the Indian pharmaceutical supply chain.
Hypertension: A Key Segment in Market Growth
Hypertension represents the principal therapeutic application for indapamide in India. The drug is marketed both as a standalone treatment and in combination with other antihypertensive agents, while Indian clinical research continues to evaluate indapamide-based treatment strategies for blood-pressure control.
The major companies operating in the India indapamide market include Servier India Private Limited, Torrent Pharmaceuticals Limited, Zydus Healthcare Limited, Eris Lifesciences Limited, and Lupin Limited, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
The Report Covers
1. India Indapamide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. India Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
3. India Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
4. India Indapamide Market Research and Analysis by Strength, 2025–2035 ($ Million)
5. India 1.25 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
6. India 2.5 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
7. India Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
8. India Indapamide Market Research and Analysis by Application, 2025–2035 ($ Million)
9. India Indapamide for Hypertension Research and Analysis by Region, 2025–2035 ($ Million)
10. India Indapamide for Edema (Fluid Retention) Research and Analysis by Region, 2025–2035 ($ Million)
11. India Indapamide for Heart Failure (Adjunct Therapy) Research and Analysis by Region, 2025–2035 ($ Million)
1. India Indapamide Market Share by Product Type, 2025 vs 2035 (%)
2. India Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. India Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. India Indapamide Market Share by Strength, 2025 vs 2035 (%)
5. India 1.25 mg Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. India 2.5 mg Indapamide Market Research and Analysis by Region, 2025 vs 2035 (%)
7. India Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. India Indapamide Market Share by Application, 2025 vs 2035 (%)
9. India Indapamide for Hypertension Market Research and Analysis by Region, 2025 vs 2035 (%)
10. India Indapamide for Edema (Fluid Retention) Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. India Indapamide for Heart Failure (Adjunct Therapy) Market Research and Analysis by Region, 2025 Vs 2035 (%)